Reports

Drug name	NICE TAs	Comments
Lebrikizumab	TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
Lenalidomide capsules	TA171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy TA322 - Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
Lenvatinib (Kisplyx®)	TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma TA551 - Lenvatinib for untreated advanced hepatocellular carcinoma TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
Letrozole tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Linzagolix (Yselty®)	TA996: Linzagolix for treating moderate to severe symptoms of uterine fibroids
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name)	TA664 - Liraglutide for managing overweight and obesity	The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name)	NICE NG28: Type 2 diabetes in adults - management	THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary.
Lorlatinib (Lorviqua®)	TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lumacaftor-ivacaftor (Orkambi®)	TA398 - Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation	NHSE commissioning statement
Lusutrombopag (Mulpleo®)	TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports